EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema

Anaraa Toishubai, Uranchimeg Davaatseren, Baasankhuu Jamyanjav, Sun Taek Lim, Bulgan Tuvaan, Munkhzaya Tsengenbayar, Munkhkhishig Batbileg, Oyunzaya Luvsantseren, Urangua Jamyansuren, Munkhsaikhan Munkhkhuyag, Unudeleg Bayaraa, Khudrenchuluun Nanjid und 3 weitere

Central Asian Journal of Medical Sciences · 2016

DOI: 10.24079/cajms.2016.01.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Central Asian Journal of Medical Sciences, 2016. Verfasst von Anaraa Toishubai und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the efficacy and safety of bevacizumab monotherapy and bevacizumab therapy combined with laser therapy versus laser monotherapy in Mongolian patients with visual impairment due to diabetic macular edema (DME).

Methods

One hundred twelve eligible patients, aged ^18 years, with type 1 or 2 diabetes mellitus and best corrected visual acuity (BCVA) in the study eye of 35 to 69 Early Treatment Diabetic Retinopathy Study letters at 4 m (Snellen equivalent: >6/60 or 10 and >15 letters and had a BCVA letter score >73 (Snellen equivalent: >6/12) with bevacizumab monotherapy (23.8% and 7.1% and 4.8%, respectively) and bevacizumab + laser (57.1% and 28.6% and 14.3%, respectively) versus laser monotherapy (0% and 0% and 0%, respectively). The mean central retinal subfield thickness was significantly reduced from baseline to month 12 with bevacizumab (-124.4 pm) and bevacizumab + laser (-129.0 pm) versus laser (-62.0 pm; both p = 0.002). Conjunctival hemorrhage was the most common ocular event. No endophthalmitis cases occurred.

Conclusion

Bevacizumab monotherapy or bevacizumab + laser showed superior BCVA improvements over macular laser treatment alone in Mongolian patients with visual impairment due to DME.

Zitieren

APA

Toishubai, A., Davaatseren, U., Jamyanjav, B., Lim, S. T., Tuvaan, B., Tsengenbayar, M., Batbileg, M., Luvsantseren, O., Jamyansuren, U., Munkhkhuyag, M., Bayaraa, U., Nanjid, K., Muktar, Y., Chandaga, U., & Ochir, C. (2016). Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema. Central Asian Journal of Medical Sciences. https://doi.org/10.24079/cajms.2016.01.008

Vancouver

Toishubai A, Davaatseren U, Jamyanjav B, Lim ST, Tuvaan B, Tsengenbayar M, et al. Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema. Central Asian Journal of Medical Sciences. 2016. doi:10.24079/cajms.2016.01.008

BibTeX
@article{Toishubai2016,
  author = {Toishubai, Anaraa and Davaatseren, Uranchimeg and Jamyanjav, Baasankhuu and Lim, Sun Taek and Tuvaan, Bulgan and Tsengenbayar, Munkhzaya and Batbileg, Munkhkhishig and Luvsantseren, Oyunzaya and Jamyansuren, Urangua and Munkhkhuyag, Munkhsaikhan and Bayaraa, Unudeleg and Nanjid, Khudrenchuluun and Muktar, Yerkyebulan and Chandaga, Unurtsetseg and Ochir, Chimedsuren},
  title = {Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema},
  journal = {Central Asian Journal of Medical Sciences},
  year = {2016},
  doi = {10.24079/cajms.2016.01.008}
}
Kostenlos starten →